PPT-EWOLUTION: 3-months outcome of Left Atrial Appendage Closur

T hrombus at the device leakage at followup device embolisation post procedural drug regimen and impact of center experience data from the prospective 1025 patients EWOLUTION Registry. Blackshear MD and John A Odell FRCSEd Division of Cardiovascular Diseases Mayo Clinic Jacksonville Jacksonville Florida and Division of Cardiovascular Surgery Mayo Clinic Rochester Minnesota Background Left atrial appendage obliteration was historic The LAA is a normal part of the heart anatomy and causes no problems in the general population However this pouch is a major source of blood clots in patients with atrial fibrillation Atrial fibrillation AF is the biggest risk factor for blood clots The following information about the WATCHMAN implant is important for you to know along with medication recommendations and common questions you may have about your implant UNDERSTANDING YOUR HEART This section will discuss the basic function of th www.watchmandevice.com. AF is a Growing Problem Associated with Greater . Morbidity and . Mortality . ~5 M. people with . AF in U.S., expected to more than double by 2050. 1. AF = most . common cardiac . versus Warfarin Therapy for Prevention of Stroke . in Patients with Atrial Fibrillation: A Randomized . Non-Inferiority Trial. David R. Holmes, MD. Vivek Y. Reddy, MD. Zoltan G. Turi, MD. Shephal K. Doshi, MD. Percutaneous. Left Atrial Appendage (LAA) Exclusion. Aaditya Vora, MD. Cardiac Electrophysiologist. Baptist heart specialists. Disclosures. None. > . 33M. people with . AF Worldwide. 1. Many patients are unprotected. Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2. , . Saibal. Kar. 3. , William O’Neill MD. 4. , . Shephal. K. . Doshi. MD. 5. , Rodney P. Horton MD. 6. , Maurice . Buchbinder. MD. 7. , Nicole T. Gordon BSEE. A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. . A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Product Overview . MKT-2387A-G. LAA Management Guidelines. MKT-2387A-G. Society. Recommendation. STS (2017). “It is REASONABLE to perform left atrial appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C limited data)” . centre. , single-blind . randomised. controlled trial. Mario . Gaudino. , MD PhD MSCE FAHA. | . Stephen and Suzanne Weiss Professor in Cardiothoracic Surgery , Weill Cornell Medicine. 2. Posterior left pericardiotomy for the prevention of postoperative atrial fibrillation after cardiac surgery: . mahsa. . . ghasemi. ASDs account for approximately 10% of all congenital heart disease and 20% to 40% of congenital heart disease occurring in adulthood.. Secundum. Atrial Septal Defect. . Secundum. Stands for electrocardiogram . ( . EKG ); it’s a record of the . heart’s . electrical activity. .. . This activity recorded in a form of waves , . each wave . has its own characteristic . Electrical activity means the depolarization and repolarization of the myocardium .